A common virus that causes meningitis and heart inflammation takes a back door approach to evade natural barriers, then exploits biological signals to infect human cells. Broadening knowledge of how viruses cause infection, a new study describes elaborate methods that the virus has evolved to bypass the bodys defenses.
This study helps to explain how group B coxsackieviruses infect cells, said Jeffrey M. Bergelson, MD, a pediatric infectious diseases specialist at The Childrens
Bergelsons study, co-authored with Carolyn B. Coyne, PhD, also of Childrens Hospital, appears in the Jan. 13 issue of the journal Cell.
Group B coxsackieviruses (CVBs) are common in people, but usually are defeated by the immune system after causing minor infections. However, CVBs may sometimes cause myocarditis, a potentially severe inflammation of the heart in children and adults, as well as viral meningitis, which inflames the lining of the brain. Rarely, the virus may lead to fatal, overwhelming infection in newborns.
CVBs typically reach people in contaminated food or water, with the virus entering cells that line the intestine, called epithelial cells. Just how the virus enters those cells has been puzzling to scientists. Bergelson previously discovered a cell receptor called the coxsackievirus and adenovirus receptor (CAR) to which the virus attaches itself. However, the CAR remains below the surface of epithelial cells, in a seemingly inaccessible location called the tight junction.
In the new study, Bergelson and Coyne found that CVBs have evolved an indirect route of attack. The virus first attaches itself to more accessible cell receptors called DAF receptors that lie exposed on the upper surface of epithelial cells.
After attaching itself to a DAF receptor, the virus triggers two signals that open the door to infection. One signal causes the virus to move into the tight junction, where it can reach the CAR. A second signal leads the virus to move deeper into cells where it can release its nucleic acid payload and complete the process of infection.
We showed for the first time that this virus is dependent on signaling pathways to drive invasion, said Bergelson. Specifically, the coxsackievirus activates kinases, enzymes that are instrumental in moving structures within cells.
These particular kinases were previously known to be active in cancers, where their signaling functions go out of control, he added. However, kinases have a normal function, in enabling cells to respond to hormones or growth factors. We showed in this study that viruses can co-opt kinase signaling processes to advance an infection.
In describing how the coxsackievirus takes advantage of signaling pathways, added Bergelson, his investigations revealed steps in a viruss life cycle that were previously unknown. Eventually this understanding may yield clinical benefits, by contributing to future therapies to block viral infections. For now, we have learned more about cell functions, and how viruses may evolve unexpected methods to force themselves into cells.
Grants from the National Institutes of Health and the American Heart Association supported this research.